This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Feb 1;76(2):236-237.

doi: 10.1001/jamaneurol.2018.4141.

Consideration of Costs and Open-Label Studies of Erenumab-Reply

Elizabeth W Loder¹, Rebecca C Burch¹

Affiliations

PMID: 30575855
DOI: 10.1001/jamaneurol.2018.4141

Comment

Consideration of Costs and Open-Label Studies of Erenumab-Reply

Elizabeth W Loder et al. JAMA Neurol. 2019.

. 2019 Feb 1;76(2):236-237.

doi: 10.1001/jamaneurol.2018.4141.

Authors

Elizabeth W Loder¹, Rebecca C Burch¹

Affiliation

¹ Division of Headache, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

PMID: 30575855
DOI: 10.1001/jamaneurol.2018.4141

No abstract available

PubMed Disclaimer

Comment on

Who Should Try New Antibody Treatments for Migraine?
Loder EW, Burch RC. Loder EW, et al. JAMA Neurol. 2018 Sep 1;75(9):1039-1040. doi: 10.1001/jamaneurol.2018.1268. JAMA Neurol. 2018. PMID: 29799961 No abstract available.
Consideration of Costs and Open-label Studies of Erenumab.
Charles JA. Charles JA. JAMA Neurol. 2019 Feb 1;76(2):236. doi: 10.1001/jamaneurol.2018.4150. JAMA Neurol. 2019. PMID: 30575850 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information